Patient Demographics at Baseline
| Demographic | Nonresponder | Responder | P |
|---|---|---|---|
| Race | |||
| Black | 3 | 1 | 0.12 |
| White | 12 | 26 | |
| Hispanic | 0 | 1 | N/A |
| Other | 1 | 0 | N/A |
| Prior treatments | |||
| Abiraterone | |||
| No | 4 | 3 | 0.39 |
| Yes | 12 | 25 | |
| Enzalutamide | |||
| No | 5 | 5 | 0.46 |
| Yes | 11 | 23 | |
| Docetaxel | |||
| No | 5 | 6 | 0.72 |
| Yes | 11 | 22 | |
| Cabazitaxel | |||
| No | 8 | 16 | 0.76 |
| Yes | 8 | 12 | |
| 223Ra | |||
| No | 15 | 23 | 0.39 |
| Yes | 1 | 5 | |
| Metastases | |||
| Bone | |||
| No | 0 | 6 | 0.07 |
| Yes | 16 | 22 | |
| Lymph node | |||
| No | 7 | 16 | 0.53 |
| Yes | 9 | 12 | |
| Liver | |||
| No | 12 | 27 | 0.05 |
| Yes | 4 | 1 | |
| Baseline labs | |||
| PSA (ng/mL) | 71.5 (4.11–824) | 88.9 (7.32–4,235.09) | 0.61 |
| Hemoglobin (g/dL) | 11.15 (7.7–14) | 11.45 (9.8–14.9) | 0.16 |
| Alkaline phosphatase (U/L) | 163 (69–582) | 81 (30–1,253) | 0.003 |
| Lactate dehydrogenase (U/L) | 249.5 (163–613) | 192 (87–695) | 0.009 |
Qualitative data are number; continuous data are median and range.